Peptide analogs for treating diseases and disorders
AssigneeKeyBioscience AG
InventorsNozer M. Mehta, William Stern, Amy M. Sturmer, Morten Asser Karsdal, Kim Henriksen
Life of this patent
Estimating the term…
Abstract
A peptide having a sequence selected from SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 and SEQ ID NO:18. Said peptide used for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of apetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test.
Claims18
A method comprising administering to the patient an effective amount of a peptide selected from the group consisting of:
- AcCSNLSTCVLGKLSQELHKLQTYPRTDVGANAP-NH2 SEQ ID NO:15,
- AcCSNLSTCVLGRLSQELHRLQTFPRTDVGANTAcY SEQ ID NO:12, and
- SuccCSNLSTCVLGKLSQELHKLQTYPRTDVGANAY-NH2 SEQ ID NO:17 to effect a weight reduction in the patient.
A method comprising administering to a patient an effective amount of a peptide selected from the group consisting of:
- AcCSNLSTCVLGKLSQELHKLQTYPRTDVGANAP-NH2 SEQ ID NO:15,
- AcCSNLSTCVLGRLSQELHRLQTFPRTDVGANTAcY SEQ ID NO:12, and
- SuccCSNLSTCVLGKLSQELHKLQTYPRTDVGANAY-NH2 SEQ ID NO:17 to effect postprandial glycemic control in the patient.
A method comprising administering to a patient an effective amount of a peptide selected from the group consisting of:
- AcCSNLSTCVLGKLSQELHKLQTYPRTDVGANAP-NH2 SEQ ID NO:15,
- AcCSNLSTCVLGRLSQELHRLQTFPRTDVGANTAcY SEQ ID NO:12, and
- SuccCSNLSTCVLGKLSQELHKLQTYPRTDVGANAY-NH2 SEQ ID NO:17 to effect an improvement in glycemic control in the patient.
Dependencies are inferred from the claim text.